Dare Bioscience Shifts Strategy Amidst Widening Losses, Boosts Cash Reserves

Ticker: DARE · Form: 10-Q · Filed: Nov 13, 2025 · CIK: 1401914

Sentiment: bearish

Topics: Biotechnology, Women's Health, SEC Filing, 10-Q Analysis, Drug Development, Commercialization Strategy, Cash Burn

Related Tickers: DARE

TL;DR

**DARE is burning cash and pivoting hard to 503B compounding to stay afloat, but it's a high-risk bet on a new commercial model.**

AI Summary

Dare Bioscience, Inc. reported a net loss of $3.56 million for the three months ended September 30, 2025, a decrease from the $4.70 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the company's net loss was $11.96 million, a significant shift from the net income of $1.45 million reported in the prior year, primarily due to a one-time gain of $20.38 million from the sale of royalty and milestone rights in 2024. Total revenue for the quarter was minimal at $2,262, down from $41,691 in Q3 2024, reflecting a substantial 94.5% decline in royalty revenue. Research and development expenses decreased by 56.2% to $1.18 million for the quarter and by 55.3% to $4.90 million for the nine-month period, indicating a shift in operational focus. General and administrative expenses increased to $2.50 million for the quarter, up from $2.04 million in Q3 2024. The company's cash and cash equivalents significantly increased to $23.08 million as of September 30, 2025, from $15.70 million at December 31, 2024, largely due to $19.66 million in net proceeds from common stock issuance. Dare Bioscience is expanding its business model to include Section 503B compounding and consumer health products for earlier market access, alongside traditional FDA approval pathways.

Why It Matters

Dare Bioscience's strategic pivot to Section 503B compounding and consumer health products signals a critical attempt to generate earlier revenue streams, which is vital for a company with declining royalty revenue and significant R&D expenses. For investors, this dual-path approach could de-risk product commercialization, but also introduces new regulatory and market acceptance challenges in a competitive women's health sector. Employees may see a shift in focus towards commercial execution and away from pure R&D. Customers could benefit from faster access to certain formulations. The broader market will watch to see if this model can successfully bridge the gap between biotech innovation and market entry, potentially influencing other small biotechs.

Risk Assessment

Risk Level: high — The company reported a net loss of $11.96 million for the nine months ended September 30, 2025, and has an accumulated deficit of $187.25 million, indicating a history of unprofitability. While cash reserves increased to $23.08 million, this was primarily from equity issuance, not operational profitability. The shift to Section 503B compounding introduces new commercialization risks, as the company lacks a proven track record and infrastructure in this area, as explicitly stated in the 'Risk Factors' section.

Analyst Insight

Investors should exercise extreme caution and closely monitor the success of Dare Bioscience's new Section 503B compounding and consumer health strategies. Given the significant accumulated deficit and reliance on equity financing, potential investors should wait for clear evidence of sustainable revenue generation and a path to profitability from these new ventures before considering an investment.

Financial Highlights

debt To Equity
9.76
revenue
$2,262
operating Margin
N/A
total Assets
$30,748,574
total Debt
$27,890,671
net Income
$-3,562,766
eps
N/A
gross Margin
N/A
cash Position
$23,075,261
revenue Growth
-94.5%

Revenue Breakdown

SegmentRevenueGrowth
Royalty revenue$2,262-94.5%

Key Numbers

Key Players & Entities

FAQ

What were Dare Bioscience's key financial results for Q3 2025?

Dare Bioscience reported a net loss of $3.56 million for the three months ended September 30, 2025, compared to a net loss of $4.70 million in the same period of 2024. Total revenue for the quarter was $2,262, a significant decrease from $41,691 in Q3 2024.

How did Dare Bioscience's cash position change in the first nine months of 2025?

Cash and cash equivalents for Dare Bioscience increased to $23.08 million as of September 30, 2025, from $15.70 million at December 31, 2024. This increase was primarily driven by $19.66 million in net proceeds from the issuance of common stock.

What is Dare Bioscience's new business strategy?

Dare Bioscience announced in March 2025 an expansion of its business model to include a dual-path approach: pursuing traditional FDA approval for proprietary formulations and seeking earlier market access via Section 503B compounding facilities and select consumer health channels.

Why did Dare Bioscience's net income shift from positive to negative for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Dare Bioscience reported a net loss of $11.96 million, a significant change from the net income of $1.45 million in the prior year. This shift is largely attributable to a one-time gain of $20.38 million from the sale of royalty and milestone rights in 202024, which did not recur in 2025.

What are the main risks associated with Dare Bioscience's operations?

Key risks for Dare Bioscience include the inability to raise additional capital, dependence on grants, inexperience in commercializing products, reliance on third parties for development and commercialization, and the potential for delays or failures in clinical trials and regulatory approvals. The company also faces risks related to changes in laws for compounded drugs under Section 503B.

How have Dare Bioscience's research and development expenses changed?

Research and development expenses for Dare Bioscience decreased significantly, falling by 56.2% to $1.18 million for the three months ended September 30, 2025, from $2.68 million in the prior year. For the nine-month period, R&D expenses dropped by 55.3% to $4.90 million from $10.97 million.

What is the significance of the increase in Dare Bioscience's common stock shares outstanding?

The number of common stock shares outstanding for Dare Bioscience increased from 8,700,386 at December 31, 2024, to 13,929,502 at September 30, 2025. This substantial increase is due to the issuance of common stock, which generated $19.66 million in net proceeds, indicating reliance on equity financing to fund operations.

What is Section 503B compounding and why is Dare Bioscience pursuing it?

Section 503B of the FDCA allows outsourcing facilities to compound and distribute certain drugs without patient-specific prescriptions. Dare Bioscience is pursuing this path to achieve earlier market access for select proprietary formulations, reflecting a shift in operational priorities towards commercial execution and potentially faster revenue generation.

What is Dare Bioscience's accumulated deficit?

As of September 30, 2025, Dare Bioscience's accumulated deficit stood at $187.25 million. This substantial deficit highlights the company's history of operating losses and the significant capital required to fund its research and development activities and new commercialization efforts.

How does Dare Bioscience's new strategy impact its competitive landscape?

Dare Bioscience's dual-path strategy, including Section 503B compounding, aims to differentiate it by potentially offering faster market access for certain products. However, it also places the company in a new competitive arena with established compounding pharmacies and consumer health brands, requiring significant investment in commercial infrastructure and market penetration.

Risk Factors

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Dare Bioscience often rely on external funding and strategic partnerships to advance their pipelines. The trend towards diversifying revenue streams through earlier market access products (like compounding and consumer health) reflects a broader industry effort to mitigate the risks associated with lengthy FDA approval processes.

Regulatory Implications

Dare Bioscience operates under stringent FDA regulations for its drug development pipeline. Any delays or failures in the approval process can have severe financial and operational consequences. The expansion into compounding pharmacies (Section 503B) introduces a different set of regulatory considerations and compliance requirements that must be carefully managed.

What Investors Should Do

  1. Monitor R&D spending and pipeline progress closely.
  2. Analyze the success of the new business model segments (compounding, consumer health).
  3. Assess the sustainability of cash burn relative to funding sources.
  4. Evaluate the impact of increased G&A expenses.

Key Dates

Glossary

Accumulated deficit
The total net losses of a company since its inception, minus any net gains. It represents the cumulative losses that have not been offset by profits. (Indicates the company's historical unprofitability and the extent of losses incurred over time.)
Royalty revenue
Income generated from licensing intellectual property or assets, where the payment is a percentage of sales or revenue generated by the licensee. (A key revenue stream for Dare Bioscience that has seen a significant decline, impacting overall financial performance.)
Research and development expenses
Costs incurred by a company in the process of developing new products or services, or improving existing ones. (A major expense category for biotech firms; a decrease may signal a strategic shift or cost-cutting measures.)
General and administrative expenses
Costs associated with the overall management and operation of a business, not directly tied to production or sales. (An increase in these expenses, despite revenue decline, warrants attention for potential operational inefficiencies or strategic investments.)
Common stock issuance
The process by which a company sells new shares of its common stock to investors, typically to raise capital. (The primary source of the company's increased cash position, highlighting reliance on external funding.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Dare Bioscience has seen a dramatic shift from net income of $1.45 million to a net loss of $11.96 million, primarily due to the absence of a significant one-time gain from asset sales in 2024. Revenue has plummeted by 94.5% year-over-year for the quarter, signaling a severe contraction in its traditional revenue streams. While R&D expenses have been reduced by 55.3% for the nine-month period, indicating a strategic pivot, general and administrative expenses have increased, raising concerns about operational efficiency amidst declining revenue.

Filing Stats: 4,450 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-11-13 16:03:26

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (Unaudited)

Item 1. Condensed Consolidated Financial Statements (Unaudited) 1

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 47

Controls and Procedures

Item 4. Controls and Procedures 47

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 48

Risk Factors

Item 1A. Risk Factors 48

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 49

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 49

Other Information

Item 5. Other Information 49

Exhibits

Item 6. Exhibits 50

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (Unaudited)

Item 1. Condensed Consolidated Financial Statements (Unaudited) Dar Bioscience, Inc. and Subsidiaries Condensed Consolidated Balance Sheets September 30, 2025 December 31, 2024 (unaudited) Assets Current assets Cash and cash equivalents $ 23,075,261 $ 15,698,174 Other receivables 369,157 229,982 Prepaid expenses 1,506,603 2,519,707 Other current assets 53,159 — Total current assets 25,004,180 18,447,863 Property and equipment, net 1,657,255 1,335,732 Operating lease right-of-use assets 824,693 1,206,942 Finance lease right-of-use asset 2,244,073 — Other non-current assets 1,018,373 1,110,594 Total assets $ 30,748,574 $ 22,101,131 Liabilities and stockholders' equity (deficit) Current liabilities Accounts payable $ 1,844,862 $ 1,455,832 Accrued expenses 2,324,931 3,042,918 Deferred grant funding 14,557,265 16,561,625 Current portion of liability related to the sale of future royalties 10,542 4,054 Current portion of lease liabilities, operating 609,224 548,638 Current portion of lease liability, finance 1,869,570 — Total current liabilities 21,216,394 21,613,067 Deferred revenue, non-current 1,000,000 1,000,000 Liability related to the sale of future royalties, net 5,220,525 4,745,770 Lease liabilities long-term, operating 288,566 754,383 Lease liability long-term, finance 165,186 — Total liabilities 27,890,671 28,113,220 Commitments and contingencies (Note 9) Stockholders' equity (deficit) Preferred stock, $ 0.01 par value, 5,000,000 shares authorized; None issued and outstanding — — Common stock, $ 0.0001 par value; 240,000,000 shares authorized; 13,929,502 and 8,700,386 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 1,393 870 Additional paid-in capital 190,499,662 169,705,480 Accumulated other comprehensive loss ( 395,966 ) ( 428,809 ) Accumulated deficit ( 187,247,186 ) ( 175,289,630 ) Total stockholders' equity (deficit) 2,857,903 ( 6,012,089 ) Total liabilities and sto

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing